Clinical trials: Bullous Dermatoses
Pemphigoid, Bullous, Adrenal Insufficiency
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
The braking of the corticotropic axis is well established during the induction phase of superpotent topical corticosteroid therapy (clobetasol propionate) in bullous pemphigoid (BP).
- Trial name
- PB-DEPIST (NCT06148090)
- Testing
- clobetasol decreasing measurement
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Bullous Pemphigoid
The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors
The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019.
- Trial name
- NCT04469582
- Where
- Greece
- Volunteers
- 113 people
- Sponsor
- University of Athens
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Bullous Pemphigoid
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Bullous pemphigoid (BP) is the most common autoimmune bullous dermatosis. It mainly affects the elderly, and its cutaneous manifestations are extremely varied.
- Trial name
- NCT03636763
- Testing
- data report
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Bullous Pemphigoid
Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.
- Trial name
- NCT00213421
- Testing
- Dermoval
- Where
- France
- Volunteers
- 330 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid (BP)
Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC)
Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity.
- Trial name
- BP-EPIC (NCT07649486)
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul Training and Research Hospital
Chronic Conjunctivitis, Stevens-Johnson Syndrome
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
A phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC) in the treatment of cicatricial conjunctivitis associated with Lyell's…
- Conditions
- Chronic Conjunctivitis, Stevens-Johnson Syndrome, Lyell Syndrome, Pemphigoid
- Trial name
- CELOPHIN (NCT05520086)
- Testing
- Single Dose, Double Dose
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Osteoporosis, Bullous Pemphigoid
Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier.
- Trial name
- DERMOS (NCT03926377)
- Testing
- bone densitometry, blood test, radiographs of the thoracic and lumbar spine
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Bullous Pemphigoid, Janus Kinase Inhibitor
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering skin disease that predominantly affects the elderly population, with rare cases reported in children and adolescents.
- Conditions
- Bullous Pemphigoid, Janus Kinase Inhibitor, Corticosteroids
- Trial name
- NCT06561256
- Testing
- Janus Kinase Inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chao Ji
Bullous Pemphigoid
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
Whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact on quality of life have been little studied.
- Trial name
- PRURIPB (NCT03272958)
- Where
- 16 sites in France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Brest
Pemphigoid, Bullous
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
- Trial name
- NCT02226146
- Testing
- Bertilimumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Bullous Pemphigoid
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease and typically affects the elderly. Clinically, BP is an intensely pruritic erythematous eruption with widespread blister formation.
- Trial name
- PB-USTE (NCT04117932)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- CHU de Reims
Bullous Pemphigoid
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and conflict the exclusion criteria will receive NPB-01(intravenous…
- Trial name
- NPB-01 (NCT00809822)
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Bullous Pemphigoid
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.
- Trial name
- NCT05649579
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Peking University First Hospital
Bullous Pemphigoid
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid.
- Trial name
- ARREST-BP (NCT05061771)
- Testing
- nomacopan (rVA576)
- Where
- 12 sites in United States, Germany and 2 more
- Sponsor
- AKARI Therapeutics
Pemphigus, Pemphigoid
Wound Dressings for Pemphigus and Pemphigoid
The purpose of this study is to compare the efficacy of four dressings (covers) namely: gauze with petrolatum , cellulose acetate with petrolatum , pure carboxymethylcellulose with silver and nanocrystalline silver to improve the…
- Trial name
- NCT02365675
- Testing
- Cotton gauze with petrolatum, Cellulose acetate with petrolatum, Nanocrystalline silver (Acticoat)
- Where
- 2 sites in Mexico
- Volunteers
- 12 people
- Sponsor
- Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
Bullous Pemphigoid
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
The purpose of this study is to evaluate the safety of efgartigimod PH20 SC over a longer period of time in adult participants with moderate-to-severe bullous pemphigoid (BP) who have completed ARGX-113-2009 study.
- Trial name
- BALLAD+ (NCT05681481)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 40 sites in United States, Australia and 15 more
- Volunteers
- 64 people
- Sponsor
- argenx
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin.
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Trial name
- NCT02960997
- Testing
- Sirolimus, 2%, Vehicle
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Bullous Pemphigoid
Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid
Bullous pemphigoid is the most common subepidermal autoimmune blistering disease of the skin in European countries, including France.
- Trial name
- Cyto-PB (NCT02883894)
- Testing
- Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
- Where
- France
- Volunteers
- 120 people
- Sponsor
- CHU de Reims